Completed

NCT Number: NCT00088036

Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder

The purpose of the protocol is to evaluate the efficacy and safety of olanzapine compared with placebo in patients with Borderline Personality Disorder (BPD).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Borderline Personality Disorder Mental Disorders Personality Disorders

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Capital Federal, Buenos Aires, Argentina

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients must be of outpatient status at Visit 1 and through Visit 2
Patients must be 18 through 65 years of age at Visit 1
Patients must meet all of the DSM-IV-TR General Diagnostic Criteria for a Personality Disorder AND Patients must meet DSM-IV-TR diagnostic criteria for BPD as determined by the DIPD-IV, confirmed by a psychiatrist with training in the evaluation and assessment of BPD.
The symptom severity as assessed by the total score of the ZAN-BPD, confirmed by a psychiatrist with training in the evaluation and assessment of BPD, must be greater than or equal to 9 at Visit 2.
Female patients of childbearing potential must test negative for pregnancy and must be using medically accepted means of contraception throughout the study. Use of any oral or injectable contraception must be initiated prior to Visit 2.

Exclusion criteria

Investigators, study site personnel directly affiliated with the study, or immediate family of investigator site personnel directly affiliated with the study. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
Persons employed by Lilly (that is, employees, temporary contract workers, or designees responsible for the conduct of the study). Immediate family of Lilly employees may participate in Lilly-sponsored clinical trials, but are not permitted to participate at a Lilly facility. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted
Have previously participated (have been randomized) or withdrawn from this study or any other Lilly sponsored study investigating olanzapine.
Have had previous treatment with olanzapine unless, in the opinion of the investigator, the patient's previous treatment was inadequate in dose or duration to provide an accurate assessment of the therapy, or the effect of olanzapine was confounded by concomitant medication.
Female patients who are either pregnant or nursing.

Treatment and study plan

Olanzapine

Drug

Primary outcomes

To assess the efficacy of olanzapine therapy (5.0-10.0 mg/day) compared with placebo in patients with BPD,as defined by DSM-IV-TR criteria,
in improving overall symptomatology as measured by the last observation carried forward (LOCF) mean change from baseline to endpoint in the ZAN-BPD total score for up to 12 weeks of double-blind treatment.

Secondary outcomes

To assess the efficacy of olanzapine 2.5 mg/day compared with placebo in patients with BPD, as defined by DSM-IV-TR criteria
in improving overall symptomatology as measured by last observation carried forward (LOCF) mean change from baseline to endpoint in the ZAN-BPD total score for up to 12 weeks of double-blind treatment
to evaluate the level of functioning as measured by LOCF mean change from baseline to endpoint on the Sheehan Disability Scale (Work, Social Life,and Family Life/Home Responsibilities)total score
and individual scores(Work, Social Life,Family Life/Home Responsibilities, Days Lost, and Days Under Productive)
to assess the reduction of aggression, suicidality, and irritability as measured by the LOCF mean change from baseline to endpoint in the rating of the Overt Aggression Scale-Modified (OAS-M) total score
to assess the reduction of self-mutilation determined by the mean frequency of self-mutilation attempts as captured on the Lifetime Self-Destructiveness scale (LSDS), which will measure both frequency and nature of attempts
The frequency of self-mutilation for each patient will be calculated as the number of self-mutilations divided by the patient's total number of study drug exposure
(Self-mutilation is defined as deliberate physical self harm without the intent to commit suicide)
to assess the reduction of suicide attempts as determined by the mean frequency of suicide attempts.
The frequency of suicide attempts for each patient will be calculated as the number of suicide attempts divided by the patient's total number of days of study drug exposure
to assess the treatment of the core domains of BPD as assessed by LOCF mean change from baseline to endpoint in each of the four ZAN-BPD domain scores (cognitive disturbances,disturbed relationships,affective disturbances,and impulsivity)
to assess the following symptom domains (paranoid ideation, psychoticism, anxiety, depression, anger/hostility, interpersonal sensitivity, phobic anxiety, obsessive-compulsive, and somatization)on the Global Severity Index of the SCL-90-R
as determined by the LOCF mean change from baseline to endpoint
to evaluate the rate of response, time in response, and time to response. Levels of response are defined as a 30% and 50% reduction in the ZAN-BPD total score from baseline (Visit 2)
to assess the treatment of depressive mood symptoms as measured by LOCF mean change from baseline to endpoint in the total score on the Montgomery-Asberg Depression Rating Scale (MADRS)
to assess the resource utilization by frequency divided by the patient's total number of days of study drug exposure for days hospitalized for physical and psychological reasons,number of hospital admissions
or medical visits(emergency department, general and special care physicians, and other mental health care professionals
to evaluate the level of functioning in patients as measured by LOCF mean change from baseline to endpoint on the GAF
to assess the safety as measured by treatment-emergency adverse events (TEAE), change in vital signs and laboratory analytes, electrocardiograms and severity of any extrapyramidal symptoms (EPS)
The Simpson Angus Scale, Abnormal Involuntary Movement Scale and Barnes Akathisia Scale will be used to measure EPS
The objectives of Study Period III (Open Label Extension Period are:
to assess the longer term safety of olanzapine for up to 12 additional weeks of therapy
as measured by TEAE, change in vital signs and laboratory analytes, ECG and severity of EPS.
to explore the efficacy of continued olanzapine treatment for up to 12 additional weeks of therapy
as measured by the ZAN-BPD total score, MADRS, Sheehan Disability Scale and LSDS
to assess resource utilization by frequency of divided by the patient's total number of days of study drug exposure for
days hospitalized for physical and psychological reasons, number of hospital admissions
or medical visits (emergency department, general and special care physicians or other mental health care professionals

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Official study title

Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Double-Blind Comparison With Placebo

Important dates

Study start: 2004
Study completion: 2006
First posted: Jul 21, 2004
Registry last updated: Jul 24, 2006

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed

Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics

NCT04130958

Behavior, Behavioral Symptoms

Boston, Massachusetts, United States

View Trial Details

Completed

Personality Change Study for Borderline Personality Disorder

NCT06005129

Borderline Personality Disorder, Mental Disorders

Lexington, Kentucky, United States

View Trial Details

Completed

Brief Admission by Self-referral for Individuals With Self-harm: Effects on Compulsory Care

NCT06406972

Behavior, Behavioral Symptoms

Lund, Skåne County, Sweden

View Trial Details

Completed

Caplyta in Borderline Personality Disorder

NCT05356013

Borderline Personality Disorder, Mental Disorders

Chicago, Illinois, United States

View Trial Details

Key information

Conditions

Age range

Sex eligibility

Study type

Phase

Primary location

Who can participate

Treatment and study plan

Olanzapine

Primary outcomes

To assess the efficacy of olanzapine therapy (5.0-10.0 mg/day) compared with placebo in patients with BPD,as defined by DSM-IV-TR criteria,

in improving overall symptomatology as measured by the last observation carried forward (LOCF) mean change from baseline to endpoint in the ZAN-BPD total score for up to 12 weeks of double-blind treatment.

Secondary outcomes

To assess the efficacy of olanzapine 2.5 mg/day compared with placebo in patients with BPD, as defined by DSM-IV-TR criteria

in improving overall symptomatology as measured by last observation carried forward (LOCF) mean change from baseline to endpoint in the ZAN-BPD total score for up to 12 weeks of double-blind treatment

to evaluate the level of functioning as measured by LOCF mean change from baseline to endpoint on the Sheehan Disability Scale (Work, Social Life,and Family Life/Home Responsibilities)total score

and individual scores(Work, Social Life,Family Life/Home Responsibilities, Days Lost, and Days Under Productive)

to assess the reduction of aggression, suicidality, and irritability as measured by the LOCF mean change from baseline to endpoint in the rating of the Overt Aggression Scale-Modified (OAS-M) total score

to assess the reduction of self-mutilation determined by the mean frequency of self-mutilation attempts as captured on the Lifetime Self-Destructiveness scale (LSDS), which will measure both frequency and nature of attempts

The frequency of self-mutilation for each patient will be calculated as the number of self-mutilations divided by the patient's total number of study drug exposure

(Self-mutilation is defined as deliberate physical self harm without the intent to commit suicide)

to assess the reduction of suicide attempts as determined by the mean frequency of suicide attempts.

The frequency of suicide attempts for each patient will be calculated as the number of suicide attempts divided by the patient's total number of days of study drug exposure

to assess the treatment of the core domains of BPD as assessed by LOCF mean change from baseline to endpoint in each of the four ZAN-BPD domain scores (cognitive disturbances,disturbed relationships,affective disturbances,and impulsivity)

to assess the following symptom domains (paranoid ideation, psychoticism, anxiety, depression, anger/hostility, interpersonal sensitivity, phobic anxiety, obsessive-compulsive, and somatization)on the Global Severity Index of the SCL-90-R

as determined by the LOCF mean change from baseline to endpoint

to evaluate the rate of response, time in response, and time to response. Levels of response are defined as a 30% and 50% reduction in the ZAN-BPD total score from baseline (Visit 2)

to assess the treatment of depressive mood symptoms as measured by LOCF mean change from baseline to endpoint in the total score on the Montgomery-Asberg Depression Rating Scale (MADRS)

to assess the resource utilization by frequency divided by the patient's total number of days of study drug exposure for days hospitalized for physical and psychological reasons,number of hospital admissions

or medical visits(emergency department, general and special care physicians, and other mental health care professionals

to evaluate the level of functioning in patients as measured by LOCF mean change from baseline to endpoint on the GAF

to assess the safety as measured by treatment-emergency adverse events (TEAE), change in vital signs and laboratory analytes, electrocardiograms and severity of any extrapyramidal symptoms (EPS)

The Simpson Angus Scale, Abnormal Involuntary Movement Scale and Barnes Akathisia Scale will be used to measure EPS

The objectives of Study Period III (Open Label Extension Period are:

to assess the longer term safety of olanzapine for up to 12 additional weeks of therapy

as measured by TEAE, change in vital signs and laboratory analytes, ECG and severity of EPS.

to explore the efficacy of continued olanzapine treatment for up to 12 additional weeks of therapy

as measured by the ZAN-BPD total score, MADRS, Sheehan Disability Scale and LSDS

to assess resource utilization by frequency of divided by the patient's total number of days of study drug exposure for

days hospitalized for physical and psychological reasons, number of hospital admissions

or medical visits (emergency department, general and special care physicians or other mental health care professionals

Sponsors and collaborators

Lead sponsor

Registry information

Official study title

Important dates

Related clinical trials

Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics

Personality Change Study for Borderline Personality Disorder

Brief Admission by Self-referral for Individuals With Self-harm: Effects on Compulsory Care

Caplyta in Borderline Personality Disorder